Insider · CIK 0001744253
Christopher J. Kirk
Files at KZR (Kezar Life Sciences, Inc.). First filing -, latest -.
In brief
Christopher J. Kirk files SEC Form 4 as CEO and director at KZR (Kezar Life Sciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Christopher J. Kirk has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | UTender of shares Common Stock | -43,134 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -4,448 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -17,792 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -8,896 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -7,117 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -87,499 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -120,000 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -8,749 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -12,499 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,999 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,999 | $0.00 | $0 | 0 | May 11, 2026 |
| May 11, 2026 | KZR Kezar Life Sciences, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -18,999 | $0.00 | $0 | 0 | May 11, 2026 |
| Jan 9, 2025 | KZR Kezar Life Sciences, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jan 13, 2025 |
| Nov 8, 2023 | KZR Kezar Life Sciences, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +875,000 | $0.00 | $0 | 875,000 | Nov 9, 2023 |
Questions about Christopher J. Kirk
Answered from the filings on this page, as of the latest one.
Is Christopher J. Kirk buying or selling?
Christopher J. Kirk has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Christopher J. Kirk's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher J. Kirk has 0.
Where does Christopher J. Kirk file Form 4?
Christopher J. Kirk has filed Form 4 at KZR (Kezar Life Sciences, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.